A Phase 3 interventional study of Abemaciclib and Abiraterone in Prostatic Neoplasms, Neoplasm Metastasis and Urogenital Neoplasms, sponsored by Eli Lilly and Company. Active, not recruiting at 266 sites in 24 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing abemaciclib in Prostatic Neoplasms — 1 open to participants now, 3 under way, 2 of them phase 3. abemaciclib · Prostatic Neoplasms.
Among the 10 studies testing abemaciclib in Prostatic Neoplasms, this one has the largest enrollment, is one of 2 that started in 2022, is the only one in phase 3, and was the 7th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →1 of the 10 studies testing abemaciclib in Prostatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Vadim S Koshkin · Sites in United States
Ages 18+
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 2
First in 2018; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 925 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 15 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 7 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
20 studies in Prostatic Neoplasms by Eli Lilly and Company: 2 open now, 8 under way, 3 of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 20 studies in Prostatic Neoplasms by Eli Lilly and Company, this one has the largest enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 2 in phase 3, and was the 15th registered.
Eli Lilly and Company’s Prostatic Neoplasms studies by the year they started, since 2007.
1 of the studies testing abemaciclib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05113537Vadim S KoshkinAbemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing abemaciclib in Prostatic Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 20 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
High-risk hormone-sensitive prostate cancer. High risk is defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 milligram (mg) abemaciclib twice daily (BID) in combination with standard doses of 1000 mg abiraterone acetate once daily and 5mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.
Drug: Abemaciclib · Drug: Abiraterone · Drug: Prednisone or Prednisolone
Participants received placebo BID in combination with standard doses of 1000 mg abiraterone acetate once daily and 5mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.
Drug: Abiraterone · Drug: Prednisone or Prednisolone · Drug: Placebo for Abemaciclib
Administered orally.
Also known as: LY2835219
Administered orally.
Drug pages: Prednisone · Prednisolone
Administered orally.
Administered orally.
Radiographic Progression-Free Survival (rPFS) Assessed by Investigator
The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.
Time frame: From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months)
Radiographic Progression-Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR)
The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.
Time frame: From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months)
Castration-resistant Prostate Cancer (CRPC)-Free Survival
CRPC-free survival is defined as the time from the date of randomization to the earliest date of castration resistance, as demonstrated by any of the following (whichever occurs earliest): Confirmed prostate-specific antigen (PSA) progression with serum testosterone ≤50 nanogram/deciliter (ng/dL) (≤1.73 nanomoles per liter(nmol/L)). Investigator-assessed radiographic progression with serum testosterone ≤50 ng/dL (≤1.73 nmol/L). Death from any cause.
Time frame: Randomization to the earliest date of PSA or radiographic progression with a testosterone level of ≤50 ng/dL; or death from any cause (up to 22 months)
Overall Survival (OS)
The OS time is measured from the date of randomization to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.
Time frame: From Date of Randomization to Date of Death Due to Any Cause (Up to 22 Months)
Time to Pain Progression
Time frame: Randomization to pain progression (up to 22 months)
Time to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Physical Well-Being Subscale
Time to deterioration in health-related quality of life (HRQoL) was defined as the time from randomization to the date of the first clinically meaningful HRQoL deterioration on 2 consecutive measurements. HRQoL evaluation was performed using the FACT-P questionnaire. Physical Well-Being subscale is a subsection of FACT-P questionnaire. FACT-P consists of 39 core items to assess health related quality of life in participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate cancer subscale (12 items). Each item is rated from 0 (Not at all) to 4 (Very much) and combined to produce subscale scores. FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to 156 with higher score indicating better quality of life. Physical well-being subscale score ranges from 0 to 28 with high score indicating better quality of life.
Time frame: Randomization to the date of the first clinically meaningful HRQoL deterioration (up to 22 months)
Time to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Prostate Cancer Subscale
Time to deterioration in health-related quality of life (HRQoL) was defined as the time from randomization to the date of the first clinically meaningful HRQoL deterioration on 2 consecutive measurements. HRQoL evaluation was performed using the FACT-P questionnaire. Prostate Cancer Subscale is a subsection of FACT-P questionnaire. FACT-P consists of 39 core items to assess health related quality of life in participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate cancer subscale (12 items). Each item is rated from 0 (Not at all) to 4 (Very much) and combined to produce subscale scores. FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to 156 with higher score indicating better quality of life. Prostate cancer subscale score ranges from 0 to 48 with high score indicating better quality of life.
Time frame: Randomization to the date of the first clinically meaningful HRQoL deterioration (up to 22 months)
Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib
Maximum plasma concentration at steady state (Cmax,ss) of abemaciclib was evaluated.
Time frame: Predose on Cycle 1 Day 1, Predose and Predose on Cycle 2 Day 1 and Predose on Cycle 3 Day 1 (28 Day Cycles)
| Milestone | Abemaciclib | Placebo |
|---|---|---|
| Started | 463 | 462 |
| Received at least one dose of study drug | 460 | 460 |
| Completed | 47 | 39 |
| Not completed | 416 | 423 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Screen failure | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: On study treatment | 408 | 418 |
The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Radiographic Progression-Free Survival (rPFS) Assessed by Investigator | NA (NA to NA) | NA (NA to NA) |
The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Radiographic Progression-Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) | NA (11.11 to NA) | NA (13.02 to NA) |
CRPC-free survival is defined as the time from the date of randomization to the earliest date of castration resistance, as demonstrated by any of the following (whichever occurs earliest): Confirmed prostate-specific antigen (PSA) progression with serum testosterone ≤50 nanogram/deciliter (ng/dL) (≤1.73 nanomoles per liter(nmol/L)). Investigator-assessed radiographic progression with serum testosterone ≤50 ng/dL (≤1.73 nmol/L). Death from any cause.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Castration-resistant Prostate Cancer (CRPC)-Free Survival | NA (14.86 to NA) | NA (NA to NA) |
The OS time is measured from the date of randomization to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
| Months | Abemaciclib | Placebo |
|---|---|---|
| Time to Pain Progression | NA (NA to NA) | 19.13 (15.35 to NA) |
Time to deterioration in health-related quality of life (HRQoL) was defined as the time from randomization to the date of the first clinically meaningful HRQoL deterioration on 2 consecutive measurements. HRQoL evaluation was performed using the FACT-P questionnaire. Physical Well-Being subscale is a subsection of FACT-P questionnaire. FACT-P consists of 39 core items to assess health related quality of life in participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate cancer subscale (12 items). Each item is rated from 0 (Not at all) to 4 (Very much) and combined to produce subscale scores. FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to 156 with higher score indicating better quality of life. Physical well-being subscale score ranges from 0 to 28 with high score indicating better quality of life.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Time to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Physical Well-Being Subscale | NA (NA to NA) | NA (NA to NA) |
Time to deterioration in health-related quality of life (HRQoL) was defined as the time from randomization to the date of the first clinically meaningful HRQoL deterioration on 2 consecutive measurements. HRQoL evaluation was performed using the FACT-P questionnaire. Prostate Cancer Subscale is a subsection of FACT-P questionnaire. FACT-P consists of 39 core items to assess health related quality of life in participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate cancer subscale (12 items). Each item is rated from 0 (Not at all) to 4 (Very much) and combined to produce subscale scores. FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to 156 with higher score indicating better quality of life. Prostate cancer subscale score ranges from 0 to 48 with high score indicating better quality of life.
| Months | Abemaciclib | Placebo |
|---|---|---|
| Time to Deterioration in Health-Related Quality of Life (HRQoL) Measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) - Prostate Cancer Subscale | NA (NA to NA) | NA (NA to NA) |
Maximum plasma concentration at steady state (Cmax,ss) of abemaciclib was evaluated.
| nanogram per milliliter (ng/mL) | Abemaciclib |
|---|---|
| Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib | 308.3 ± 50 |
Collected over Baseline up to 22 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abemaciclib | 47/460 (10.2%) | 145/460 (31.5%) | 445/460 (96.7%) |
| Placebo | 32/460 (7%) | 68/460 (14.8%) | 380/460 (82.6%) |
| Event | Abemaciclib | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 19/460 | 4/460 |
| Urinary tract infectionInfections and infestations | 11/460 | 3/460 |
| AnaemiaBlood and lymphatic system disorders | 9/460 | 0/460 |
| HypokalaemiaMetabolism and nutrition disorders | 9/460 | 3/460 |
| Acute kidney injuryRenal and urinary disorders | 8/460 | 0/460 |
| FatigueGeneral disorders | 7/460 | 1/460 |
| Cardiac failureCardiac disorders | 5/460 | 2/460 |
| Covid-19Infections and infestations | 5/460 | 3/460 |
| Atrial fibrillationCardiac disorders | 4/460 | 2/460 |
| Myocardial infarctionCardiac disorders | 4/460 | 4/460 |
| Event | Abemaciclib | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 301/460 | 62/460 |
| AnaemiaBlood and lymphatic system disorders | 252/460 | 58/460 |
| NeutropeniaBlood and lymphatic system disorders | 217/460 | 13/460 |
| FatigueGeneral disorders | 178/460 | 91/460 |
| HypokalaemiaMetabolism and nutrition disorders | 133/460 | 63/460 |
| Blood creatinine increasedInvestigations | 130/460 | 17/460 |
| LeukopeniaBlood and lymphatic system disorders | 126/460 | 10/460 |
| ThrombocytopeniaBlood and lymphatic system disorders | 125/460 | 14/460 |
| NauseaGastrointestinal disorders | 116/460 | 41/460 |
| Hot flushVascular disorders | 69/460 | 98/460 |
All randomized participants.
| Age, Continuous(years) | Abemaciclib | Placebo | Total |
|---|---|---|---|
| Mean | 68.80 ± 8.16 | 69.30 ± 8.07 | 69.00 ± 8.11 |
| Sex: Female, Male(Participants) | Abemaciclib | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 463 | 462 | 925 |
| Ethnicity (NIH/OMB)(Participants) | Abemaciclib | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 115 | 126 | 241 |
| Not Hispanic or Latino | 276 | 271 | 547 |
| Unknown or Not Reported | 72 | 65 | 137 |
| Race (NIH/OMB)(Participants) | Abemaciclib | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 27 | 27 | 54 |
| Asian | 122 | 120 | 242 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 17 | 15 | 32 |
| White | 278 | 286 | 564 |
| More than one race | 9 | 5 | 14 |
| Unknown or Not Reported | 9 | 9 | 18 |
| Region of Enrollment(Participants) | Abemaciclib | Placebo | Total |
|---|---|---|---|
| Argentina | 40 | 39 | 79 |
| Australia | 28 | 29 | 57 |
| Belgium | 3 | 0 | 3 |
| Brazil | 46 | 53 | 99 |
| Canada | 1 | 1 | 2 |
| China | 65 | 70 | 135 |
| Czechia | 15 | 11 | 26 |
| France | 14 | 9 | 23 |
| Germany | 24 | 22 | 46 |
| Greece | 2 | 4 | 6 |
| Hungary | 5 | 5 | 10 |
| Israel | 7 | 9 | 16 |
| Italy | 12 | 12 | 24 |
| Japan | 39 | 30 | 69 |
| Mexico | 34 | 34 | 68 |
| Netherlands | 2 | 5 | 7 |
| Poland | 12 | 14 | 26 |
| Romania | 3 | 2 | 5 |
| South Korea | 7 | 4 | 11 |
| Spain | 16 | 14 | 30 |
| Taiwan | 8 | 7 | 15 |
| Turkey | 21 | 20 | 41 |
| United Kingdom | 7 | 1 | 8 |
| United States | 52 | 67 | 119 |
Showing the first 100 of 266 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2022 to primary completion in Feb 2024, 22 months.
Results were first posted in Jun 2025, 1 year 4 months after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 22 months is below that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib